Work

MA15.08 Multicenter Phase II Trial of LN-145 TIL Cell Therapy plus Pembrolizumab in Patients with ICI-Naïve Metastatic NSCLC

Year: 2023

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2023.09.225

Authors: A.J. Schoenfeld, K. He, J. Chesney, E. Garon, J. Nieva, A. Sacher, S. Lee, F. Graf Finckenstein, R. Fiaz, M. Catlett, G. Chen, V. Gontcharova, B.C. Creelan

Institutions: Memorial Sloan Kettering Cancer Center, The Ohio State University, University of Louisville, University of California, Los Angeles, University of Southern California, Princess Margaret Cancer Centre, Fred Hutch Cancer Center, Iovance Biotherapeutics (United States), Moffitt Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4388045030

Cites:

Cited by: 7

Related to: 10